Financial analysts covering Puma Biotechnology (PBYI) provide forecasts that generally reflect a blend of cautious optimism regarding its commercial oncology product sales and typical clinical-stage volatility. Stock projections are heavily dependent on quarterly revenue growth from its core commercial therapy, effective expense management, and the potential advancement of its pipeline candidate clinical trials.